About AIV
Advanced In Vitro, LLC was founded by Dr. Holger Behrsing to continue developing, and promote the awareness for, predictive in vitro models that are effective in reducing product development costs and eliminating animal research. He double majored in Biological Sciences and German (Bachelor’s degree from UC Santa Barbara), allowing him to study abroad in Germany and also conduct research at the Max-Planck Institute for Experimental Medicine before returning to the United States. While at the University of California at Davis he earned his Ph.D. in Pharmacology and Toxicology researching neuronal cellular signal transduction mechanisms. As a post-doctoral researcher at SRI International, he established 3-dimensional test systems modeling the liver and lung. Subsequently as PI, he continued to advance these models under two National Cancer Institute (NCI) R33 fast track funding awards, and ultimately relocated to the East Coast to Head the Predictive Toxicology Lab Section (Leidos Biomedical Research, Inc., formerly SAIC-Frederick, Inc.), closely supporting NCI efforts.
Dr. Behrsing is the Head of Respiratory Toxicology at the Institute for In Vitro Sciences, Inc. in Gaithersburg, Maryland. He served on Environmental Protection Agency’s Scientific Advisory Panel reviewing, “A Case Study Using a New Approach Methodology”, and as an invited speaker, presented on the use of non-animal methods at the National Academies of Sciences, Engineering, and Medicine for a workshop evaluating the health effects of electronic nicotine delivery systems. He routinely attends and speaks at international meetings and workshops, highlighting the utilization and advances made in non-animal test systems for respiratory toxicology. He has authored/co-authored numerous peer reviewed articles and poster presentations and previously presented on precision-cut lung slices as a platform speaker, as well as chairing various sessions at the annual SOT meeting. In 2020 he was elected as Councilor in the Inhalation and Respiratory Specialty Section.
"It is said the 21st century will see amazing advances in the field of biotechnology. I firmly believe the conception, development, and pragmatic application of innovative in vitro systems that accurately predict human response will redefine currently accepted product development practices." Dr. Holger P. Behrsing, Founder